Global Afatinib Dimaleate Market 2023 by Company, Regions, Type and Application, Forecast to 2029
Page: 124
Published Date: 11 Jan 2023
Category: Pharma & Healthcare
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
Afatinib dimaleate is an oral molecular targeted drug developed and produced by Boehringer Ingelheim, Germany. It is a TKIs with strong and irreversible dual inhibitory effect on EGFR and HER2, and was approved by THE US FDA in July 2013.It is not only suitable for first-line treatment of metastatic NSCLC with EGFR exon 19 deletion mutation or exon 21 (L858R) replacement mutation, but also a second - and third-line target drug for egFR-TKIS resistance.
According to our (Global Info Research) latest study, the global Afatinib Dimaleate market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Clinical studies have shown that afatinib dimaleate reduces the risk of both cancer progression and death by 19% compared with first-generation EGFR TKI erlotinib, and significantly improves disease control rates, quality of life, and control of cancer symptoms.Prior to the Approval in China, afatinib has been approved in more than 70 countries for the treatment of PATIENTS with EGFR mutation-positive non-small cell lung cancer, and has become the preferred egFR-targeting drug in many countries.In addition, the drug was approved in 2016 by the US FDA and the European Union respectively for patients with advanced lung squamous cell carcinoma whose disease worsens during or after platinum-based chemotherapy.At present, the drug has been included in the medical insurance in China, and it can be expected that the market size of this product will gradually expand in the future.
This report is a detailed and comprehensive analysis for global Afatinib Dimaleate market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Afatinib Dimaleate market size and forecasts, in consumption value ($ Million), 2018-2029
Global Afatinib Dimaleate market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Afatinib Dimaleate market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Afatinib Dimaleate market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Afatinib Dimaleate
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Afatinib Dimaleate market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Boehringer Ingelheim Pharmaceuticals, APExBIO Technology LLC, Carbosynth Ltd, Biorbyt and Cayman Chemical Company, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Afatinib Dimaleate market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
20 mg
30 mg
40 mg
Market segment by Application
Treatment of EGFR Mutated Non-Small Cell Lung Cancer
Treatment of NSCLC Patients with Squamous Cell Carcinoma Histologically
Market segment by players, this report covers
Boehringer Ingelheim Pharmaceuticals
APExBIO Technology LLC
Carbosynth Ltd
Biorbyt
Cayman Chemical Company
Target Molecule Corp.
Frontier Specialty Chemicals
Combi-Blocks
Selleck Chemicals
AvaChem Scientific
Advanced ChemBlocks Inc
Glpbio
Nanjing Xize Pharmaceutical Technology Co., Ltd
Shandong Haiwo Biotechnology Co., Ltd
J&K Scientific
Shanghai McLin Biochemical Technology Co., Ltd
Beijing Sjar Technology Development Co., Ltd.
Beijing Wokai Biotechnology Co., Ltd
Ningbo Zhenlei Chemical Co., Ltd.
Beijing Mreda Technology Co., Ltd
MedBio Pharmaceutical Technology Inc
Shanghai Dibai Biotechnology Co., Ltd
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Afatinib Dimaleate product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Afatinib Dimaleate, with revenue, gross margin and global market share of Afatinib Dimaleate from 2018 to 2023.
Chapter 3, the Afatinib Dimaleate competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Afatinib Dimaleate market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Afatinib Dimaleate.
Chapter 13, to describe Afatinib Dimaleate research findings and conclusion.
Table of Contents
1 Market Overview
1.1 Product Overview and Scope of Afatinib Dimaleate
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Afatinib Dimaleate by Type
1.3.1 Overview: Global Afatinib Dimaleate Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Afatinib Dimaleate Consumption Value Market Share by Type in 2022
1.3.3 20 mg
1.3.4 30 mg
1.3.5 40 mg
1.4 Global Afatinib Dimaleate Market by Application
1.4.1 Overview: Global Afatinib Dimaleate Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Treatment of EGFR Mutated Non-Small Cell Lung Cancer
1.4.3 Treatment of NSCLC Patients with Squamous Cell Carcinoma Histologically
1.5 Global Afatinib Dimaleate Market Size & Forecast
1.6 Global Afatinib Dimaleate Market Size and Forecast by Region
1.6.1 Global Afatinib Dimaleate Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Afatinib Dimaleate Market Size by Region, (2018-2029)
1.6.3 North America Afatinib Dimaleate Market Size and Prospect (2018-2029)
1.6.4 Europe Afatinib Dimaleate Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Afatinib Dimaleate Market Size and Prospect (2018-2029)
1.6.6 South America Afatinib Dimaleate Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Afatinib Dimaleate Market Size and Prospect (2018-2029)
2.1 Boehringer Ingelheim Pharmaceuticals
2.1.1 Boehringer Ingelheim Pharmaceuticals Details
2.1.2 Boehringer Ingelheim Pharmaceuticals Major Business
2.1.3 Boehringer Ingelheim Pharmaceuticals Afatinib Dimaleate Product and Solutions
2.1.4 Boehringer Ingelheim Pharmaceuticals Afatinib Dimaleate Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Boehringer Ingelheim Pharmaceuticals Recent Developments and Future Plans
2.2 APExBIO Technology LLC
2.2.1 APExBIO Technology LLC Details
2.2.2 APExBIO Technology LLC Major Business
2.2.3 APExBIO Technology LLC Afatinib Dimaleate Product and Solutions
2.2.4 APExBIO Technology LLC Afatinib Dimaleate Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 APExBIO Technology LLC Recent Developments and Future Plans
2.3 Carbosynth Ltd
2.3.1 Carbosynth Ltd Details
2.3.2 Carbosynth Ltd Major Business
2.3.3 Carbosynth Ltd Afatinib Dimaleate Product and Solutions
2.3.4 Carbosynth Ltd Afatinib Dimaleate Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Carbosynth Ltd Recent Developments and Future Plans
2.4 Biorbyt
2.4.1 Biorbyt Details
2.4.2 Biorbyt Major Business
2.4.3 Biorbyt Afatinib Dimaleate Product and Solutions
2.4.4 Biorbyt Afatinib Dimaleate Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Biorbyt Recent Developments and Future Plans
2.5 Cayman Chemical Company
2.5.1 Cayman Chemical Company Details
2.5.2 Cayman Chemical Company Major Business
2.5.3 Cayman Chemical Company Afatinib Dimaleate Product and Solutions
2.5.4 Cayman Chemical Company Afatinib Dimaleate Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Cayman Chemical Company Recent Developments and Future Plans
2.6 Target Molecule Corp.
2.6.1 Target Molecule Corp. Details
2.6.2 Target Molecule Corp. Major Business
2.6.3 Target Molecule Corp. Afatinib Dimaleate Product and Solutions
2.6.4 Target Molecule Corp. Afatinib Dimaleate Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Target Molecule Corp. Recent Developments and Future Plans
2.7 Frontier Specialty Chemicals
2.7.1 Frontier Specialty Chemicals Details
2.7.2 Frontier Specialty Chemicals Major Business
2.7.3 Frontier Specialty Chemicals Afatinib Dimaleate Product and Solutions
2.7.4 Frontier Specialty Chemicals Afatinib Dimaleate Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Frontier Specialty Chemicals Recent Developments and Future Plans
2.8 Combi-Blocks
2.8.1 Combi-Blocks Details
2.8.2 Combi-Blocks Major Business
2.8.3 Combi-Blocks Afatinib Dimaleate Product and Solutions
2.8.4 Combi-Blocks Afatinib Dimaleate Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Combi-Blocks Recent Developments and Future Plans
2.9 Selleck Chemicals
2.9.1 Selleck Chemicals Details
2.9.2 Selleck Chemicals Major Business
2.9.3 Selleck Chemicals Afatinib Dimaleate Product and Solutions
2.9.4 Selleck Chemicals Afatinib Dimaleate Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Selleck Chemicals Recent Developments and Future Plans
2.10 AvaChem Scientific
2.10.1 AvaChem Scientific Details
2.10.2 AvaChem Scientific Major Business
2.10.3 AvaChem Scientific Afatinib Dimaleate Product and Solutions
2.10.4 AvaChem Scientific Afatinib Dimaleate Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 AvaChem Scientific Recent Developments and Future Plans
2.11 Advanced ChemBlocks Inc
2.11.1 Advanced ChemBlocks Inc Details
2.11.2 Advanced ChemBlocks Inc Major Business
2.11.3 Advanced ChemBlocks Inc Afatinib Dimaleate Product and Solutions
2.11.4 Advanced ChemBlocks Inc Afatinib Dimaleate Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Advanced ChemBlocks Inc Recent Developments and Future Plans
2.12 Glpbio
2.12.1 Glpbio Details
2.12.2 Glpbio Major Business
2.12.3 Glpbio Afatinib Dimaleate Product and Solutions
2.12.4 Glpbio Afatinib Dimaleate Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Glpbio Recent Developments and Future Plans
2.13 Nanjing Xize Pharmaceutical Technology Co., Ltd
2.13.1 Nanjing Xize Pharmaceutical Technology Co., Ltd Details
2.13.2 Nanjing Xize Pharmaceutical Technology Co., Ltd Major Business
2.13.3 Nanjing Xize Pharmaceutical Technology Co., Ltd Afatinib Dimaleate Product and Solutions
2.13.4 Nanjing Xize Pharmaceutical Technology Co., Ltd Afatinib Dimaleate Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Nanjing Xize Pharmaceutical Technology Co., Ltd Recent Developments and Future Plans
2.14 Shandong Haiwo Biotechnology Co., Ltd
2.14.1 Shandong Haiwo Biotechnology Co., Ltd Details
2.14.2 Shandong Haiwo Biotechnology Co., Ltd Major Business
2.14.3 Shandong Haiwo Biotechnology Co., Ltd Afatinib Dimaleate Product and Solutions
2.14.4 Shandong Haiwo Biotechnology Co., Ltd Afatinib Dimaleate Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Shandong Haiwo Biotechnology Co., Ltd Recent Developments and Future Plans
2.15 J&K Scientific
2.15.1 J&K Scientific Details
2.15.2 J&K Scientific Major Business
2.15.3 J&K Scientific Afatinib Dimaleate Product and Solutions
2.15.4 J&K Scientific Afatinib Dimaleate Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 J&K Scientific Recent Developments and Future Plans
2.16 Shanghai McLin Biochemical Technology Co., Ltd
2.16.1 Shanghai McLin Biochemical Technology Co., Ltd Details
2.16.2 Shanghai McLin Biochemical Technology Co., Ltd Major Business
2.16.3 Shanghai McLin Biochemical Technology Co., Ltd Afatinib Dimaleate Product and Solutions
2.16.4 Shanghai McLin Biochemical Technology Co., Ltd Afatinib Dimaleate Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Shanghai McLin Biochemical Technology Co., Ltd Recent Developments and Future Plans
2.17 Beijing Sjar Technology Development Co., Ltd.
2.17.1 Beijing Sjar Technology Development Co., Ltd. Details
2.17.2 Beijing Sjar Technology Development Co., Ltd. Major Business
2.17.3 Beijing Sjar Technology Development Co., Ltd. Afatinib Dimaleate Product and Solutions
2.17.4 Beijing Sjar Technology Development Co., Ltd. Afatinib Dimaleate Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Beijing Sjar Technology Development Co., Ltd. Recent Developments and Future Plans
2.18 Beijing Wokai Biotechnology Co., Ltd
2.18.1 Beijing Wokai Biotechnology Co., Ltd Details
2.18.2 Beijing Wokai Biotechnology Co., Ltd Major Business
2.18.3 Beijing Wokai Biotechnology Co., Ltd Afatinib Dimaleate Product and Solutions
2.18.4 Beijing Wokai Biotechnology Co., Ltd Afatinib Dimaleate Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Beijing Wokai Biotechnology Co., Ltd Recent Developments and Future Plans
2.19 Ningbo Zhenlei Chemical Co., Ltd.
2.19.1 Ningbo Zhenlei Chemical Co., Ltd. Details
2.19.2 Ningbo Zhenlei Chemical Co., Ltd. Major Business
2.19.3 Ningbo Zhenlei Chemical Co., Ltd. Afatinib Dimaleate Product and Solutions
2.19.4 Ningbo Zhenlei Chemical Co., Ltd. Afatinib Dimaleate Revenue, Gross Margin and Market Share (2018-2023)
2.19.5 Ningbo Zhenlei Chemical Co., Ltd. Recent Developments and Future Plans
2.20 Beijing Mreda Technology Co., Ltd
2.20.1 Beijing Mreda Technology Co., Ltd Details
2.20.2 Beijing Mreda Technology Co., Ltd Major Business
2.20.3 Beijing Mreda Technology Co., Ltd Afatinib Dimaleate Product and Solutions
2.20.4 Beijing Mreda Technology Co., Ltd Afatinib Dimaleate Revenue, Gross Margin and Market Share (2018-2023)
2.20.5 Beijing Mreda Technology Co., Ltd Recent Developments and Future Plans
2.21 MedBio Pharmaceutical Technology Inc
2.21.1 MedBio Pharmaceutical Technology Inc Details
2.21.2 MedBio Pharmaceutical Technology Inc Major Business
2.21.3 MedBio Pharmaceutical Technology Inc Afatinib Dimaleate Product and Solutions
2.21.4 MedBio Pharmaceutical Technology Inc Afatinib Dimaleate Revenue, Gross Margin and Market Share (2018-2023)
2.21.5 MedBio Pharmaceutical Technology Inc Recent Developments and Future Plans
2.22 Shanghai Dibai Biotechnology Co., Ltd
2.22.1 Shanghai Dibai Biotechnology Co., Ltd Details
2.22.2 Shanghai Dibai Biotechnology Co., Ltd Major Business
2.22.3 Shanghai Dibai Biotechnology Co., Ltd Afatinib Dimaleate Product and Solutions
2.22.4 Shanghai Dibai Biotechnology Co., Ltd Afatinib Dimaleate Revenue, Gross Margin and Market Share (2018-2023)
2.22.5 Shanghai Dibai Biotechnology Co., Ltd Recent Developments and Future Plans
3.1 Global Afatinib Dimaleate Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Afatinib Dimaleate by Company Revenue
3.2.2 Top 3 Afatinib Dimaleate Players Market Share in 2022
3.2.3 Top 6 Afatinib Dimaleate Players Market Share in 2022
3.3 Afatinib Dimaleate Market: Overall Company Footprint Analysis
3.3.1 Afatinib Dimaleate Market: Region Footprint
3.3.2 Afatinib Dimaleate Market: Company Product Type Footprint
3.3.3 Afatinib Dimaleate Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4.1 Global Afatinib Dimaleate Consumption Value and Market Share by Type (2018-2023)
4.2 Global Afatinib Dimaleate Market Forecast by Type (2024-2029)
5.1 Global Afatinib Dimaleate Consumption Value Market Share by Application (2018-2023)
5.2 Global Afatinib Dimaleate Market Forecast by Application (2024-2029)
6.1 North America Afatinib Dimaleate Consumption Value by Type (2018-2029)
6.2 North America Afatinib Dimaleate Consumption Value by Application (2018-2029)
6.3 North America Afatinib Dimaleate Market Size by Country
6.3.1 North America Afatinib Dimaleate Consumption Value by Country (2018-2029)
6.3.2 United States Afatinib Dimaleate Market Size and Forecast (2018-2029)
6.3.3 Canada Afatinib Dimaleate Market Size and Forecast (2018-2029)
6.3.4 Mexico Afatinib Dimaleate Market Size and Forecast (2018-2029)
7.1 Europe Afatinib Dimaleate Consumption Value by Type (2018-2029)
7.2 Europe Afatinib Dimaleate Consumption Value by Application (2018-2029)
7.3 Europe Afatinib Dimaleate Market Size by Country
7.3.1 Europe Afatinib Dimaleate Consumption Value by Country (2018-2029)
7.3.2 Germany Afatinib Dimaleate Market Size and Forecast (2018-2029)
7.3.3 France Afatinib Dimaleate Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Afatinib Dimaleate Market Size and Forecast (2018-2029)
7.3.5 Russia Afatinib Dimaleate Market Size and Forecast (2018-2029)
7.3.6 Italy Afatinib Dimaleate Market Size and Forecast (2018-2029)
8.1 Asia-Pacific Afatinib Dimaleate Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Afatinib Dimaleate Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Afatinib Dimaleate Market Size by Region
8.3.1 Asia-Pacific Afatinib Dimaleate Consumption Value by Region (2018-2029)
8.3.2 China Afatinib Dimaleate Market Size and Forecast (2018-2029)
8.3.3 Japan Afatinib Dimaleate Market Size and Forecast (2018-2029)
8.3.4 South Korea Afatinib Dimaleate Market Size and Forecast (2018-2029)
8.3.5 India Afatinib Dimaleate Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Afatinib Dimaleate Market Size and Forecast (2018-2029)
8.3.7 Australia Afatinib Dimaleate Market Size and Forecast (2018-2029)
9.1 South America Afatinib Dimaleate Consumption Value by Type (2018-2029)
9.2 South America Afatinib Dimaleate Consumption Value by Application (2018-2029)
9.3 South America Afatinib Dimaleate Market Size by Country
9.3.1 South America Afatinib Dimaleate Consumption Value by Country (2018-2029)
9.3.2 Brazil Afatinib Dimaleate Market Size and Forecast (2018-2029)
9.3.3 Argentina Afatinib Dimaleate Market Size and Forecast (2018-2029)
10.1 Middle East & Africa Afatinib Dimaleate Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Afatinib Dimaleate Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Afatinib Dimaleate Market Size by Country
10.3.1 Middle East & Africa Afatinib Dimaleate Consumption Value by Country (2018-2029)
10.3.2 Turkey Afatinib Dimaleate Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Afatinib Dimaleate Market Size and Forecast (2018-2029)
10.3.4 UAE Afatinib Dimaleate Market Size and Forecast (2018-2029)
11.1 Afatinib Dimaleate Market Drivers
11.2 Afatinib Dimaleate Market Restraints
11.3 Afatinib Dimaleate Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12.1 Afatinib Dimaleate Industry Chain
12.2 Afatinib Dimaleate Upstream Analysis
12.3 Afatinib Dimaleate Midstream Analysis
12.4 Afatinib Dimaleate Downstream Analysis
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table of Figures
List of Tables
Table 1. Global Afatinib Dimaleate Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Afatinib Dimaleate Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Afatinib Dimaleate Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Afatinib Dimaleate Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Boehringer Ingelheim Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 6. Boehringer Ingelheim Pharmaceuticals Major Business
Table 7. Boehringer Ingelheim Pharmaceuticals Afatinib Dimaleate Product and Solutions
Table 8. Boehringer Ingelheim Pharmaceuticals Afatinib Dimaleate Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Boehringer Ingelheim Pharmaceuticals Recent Developments and Future Plans
Table 10. APExBIO Technology LLC Company Information, Head Office, and Major Competitors
Table 11. APExBIO Technology LLC Major Business
Table 12. APExBIO Technology LLC Afatinib Dimaleate Product and Solutions
Table 13. APExBIO Technology LLC Afatinib Dimaleate Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. APExBIO Technology LLC Recent Developments and Future Plans
Table 15. Carbosynth Ltd Company Information, Head Office, and Major Competitors
Table 16. Carbosynth Ltd Major Business
Table 17. Carbosynth Ltd Afatinib Dimaleate Product and Solutions
Table 18. Carbosynth Ltd Afatinib Dimaleate Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Carbosynth Ltd Recent Developments and Future Plans
Table 20. Biorbyt Company Information, Head Office, and Major Competitors
Table 21. Biorbyt Major Business
Table 22. Biorbyt Afatinib Dimaleate Product and Solutions
Table 23. Biorbyt Afatinib Dimaleate Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Biorbyt Recent Developments and Future Plans
Table 25. Cayman Chemical Company Company Information, Head Office, and Major Competitors
Table 26. Cayman Chemical Company Major Business
Table 27. Cayman Chemical Company Afatinib Dimaleate Product and Solutions
Table 28. Cayman Chemical Company Afatinib Dimaleate Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Cayman Chemical Company Recent Developments and Future Plans
Table 30. Target Molecule Corp. Company Information, Head Office, and Major Competitors
Table 31. Target Molecule Corp. Major Business
Table 32. Target Molecule Corp. Afatinib Dimaleate Product and Solutions
Table 33. Target Molecule Corp. Afatinib Dimaleate Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Target Molecule Corp. Recent Developments and Future Plans
Table 35. Frontier Specialty Chemicals Company Information, Head Office, and Major Competitors
Table 36. Frontier Specialty Chemicals Major Business
Table 37. Frontier Specialty Chemicals Afatinib Dimaleate Product and Solutions
Table 38. Frontier Specialty Chemicals Afatinib Dimaleate Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Frontier Specialty Chemicals Recent Developments and Future Plans
Table 40. Combi-Blocks Company Information, Head Office, and Major Competitors
Table 41. Combi-Blocks Major Business
Table 42. Combi-Blocks Afatinib Dimaleate Product and Solutions
Table 43. Combi-Blocks Afatinib Dimaleate Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Combi-Blocks Recent Developments and Future Plans
Table 45. Selleck Chemicals Company Information, Head Office, and Major Competitors
Table 46. Selleck Chemicals Major Business
Table 47. Selleck Chemicals Afatinib Dimaleate Product and Solutions
Table 48. Selleck Chemicals Afatinib Dimaleate Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Selleck Chemicals Recent Developments and Future Plans
Table 50. AvaChem Scientific Company Information, Head Office, and Major Competitors
Table 51. AvaChem Scientific Major Business
Table 52. AvaChem Scientific Afatinib Dimaleate Product and Solutions
Table 53. AvaChem Scientific Afatinib Dimaleate Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. AvaChem Scientific Recent Developments and Future Plans
Table 55. Advanced ChemBlocks Inc Company Information, Head Office, and Major Competitors
Table 56. Advanced ChemBlocks Inc Major Business
Table 57. Advanced ChemBlocks Inc Afatinib Dimaleate Product and Solutions
Table 58. Advanced ChemBlocks Inc Afatinib Dimaleate Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Advanced ChemBlocks Inc Recent Developments and Future Plans
Table 60. Glpbio Company Information, Head Office, and Major Competitors
Table 61. Glpbio Major Business
Table 62. Glpbio Afatinib Dimaleate Product and Solutions
Table 63. Glpbio Afatinib Dimaleate Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Glpbio Recent Developments and Future Plans
Table 65. Nanjing Xize Pharmaceutical Technology Co., Ltd Company Information, Head Office, and Major Competitors
Table 66. Nanjing Xize Pharmaceutical Technology Co., Ltd Major Business
Table 67. Nanjing Xize Pharmaceutical Technology Co., Ltd Afatinib Dimaleate Product and Solutions
Table 68. Nanjing Xize Pharmaceutical Technology Co., Ltd Afatinib Dimaleate Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Nanjing Xize Pharmaceutical Technology Co., Ltd Recent Developments and Future Plans
Table 70. Shandong Haiwo Biotechnology Co., Ltd Company Information, Head Office, and Major Competitors
Table 71. Shandong Haiwo Biotechnology Co., Ltd Major Business
Table 72. Shandong Haiwo Biotechnology Co., Ltd Afatinib Dimaleate Product and Solutions
Table 73. Shandong Haiwo Biotechnology Co., Ltd Afatinib Dimaleate Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Shandong Haiwo Biotechnology Co., Ltd Recent Developments and Future Plans
Table 75. J&K Scientific Company Information, Head Office, and Major Competitors
Table 76. J&K Scientific Major Business
Table 77. J&K Scientific Afatinib Dimaleate Product and Solutions
Table 78. J&K Scientific Afatinib Dimaleate Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. J&K Scientific Recent Developments and Future Plans
Table 80. Shanghai McLin Biochemical Technology Co., Ltd Company Information, Head Office, and Major Competitors
Table 81. Shanghai McLin Biochemical Technology Co., Ltd Major Business
Table 82. Shanghai McLin Biochemical Technology Co., Ltd Afatinib Dimaleate Product and Solutions
Table 83. Shanghai McLin Biochemical Technology Co., Ltd Afatinib Dimaleate Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 84. Shanghai McLin Biochemical Technology Co., Ltd Recent Developments and Future Plans
Table 85. Beijing Sjar Technology Development Co., Ltd. Company Information, Head Office, and Major Competitors
Table 86. Beijing Sjar Technology Development Co., Ltd. Major Business
Table 87. Beijing Sjar Technology Development Co., Ltd. Afatinib Dimaleate Product and Solutions
Table 88. Beijing Sjar Technology Development Co., Ltd. Afatinib Dimaleate Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Beijing Sjar Technology Development Co., Ltd. Recent Developments and Future Plans
Table 90. Beijing Wokai Biotechnology Co., Ltd Company Information, Head Office, and Major Competitors
Table 91. Beijing Wokai Biotechnology Co., Ltd Major Business
Table 92. Beijing Wokai Biotechnology Co., Ltd Afatinib Dimaleate Product and Solutions
Table 93. Beijing Wokai Biotechnology Co., Ltd Afatinib Dimaleate Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 94. Beijing Wokai Biotechnology Co., Ltd Recent Developments and Future Plans
Table 95. Ningbo Zhenlei Chemical Co., Ltd. Company Information, Head Office, and Major Competitors
Table 96. Ningbo Zhenlei Chemical Co., Ltd. Major Business
Table 97. Ningbo Zhenlei Chemical Co., Ltd. Afatinib Dimaleate Product and Solutions
Table 98. Ningbo Zhenlei Chemical Co., Ltd. Afatinib Dimaleate Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 99. Ningbo Zhenlei Chemical Co., Ltd. Recent Developments and Future Plans
Table 100. Beijing Mreda Technology Co., Ltd Company Information, Head Office, and Major Competitors
Table 101. Beijing Mreda Technology Co., Ltd Major Business
Table 102. Beijing Mreda Technology Co., Ltd Afatinib Dimaleate Product and Solutions
Table 103. Beijing Mreda Technology Co., Ltd Afatinib Dimaleate Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 104. Beijing Mreda Technology Co., Ltd Recent Developments and Future Plans
Table 105. MedBio Pharmaceutical Technology Inc Company Information, Head Office, and Major Competitors
Table 106. MedBio Pharmaceutical Technology Inc Major Business
Table 107. MedBio Pharmaceutical Technology Inc Afatinib Dimaleate Product and Solutions
Table 108. MedBio Pharmaceutical Technology Inc Afatinib Dimaleate Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 109. MedBio Pharmaceutical Technology Inc Recent Developments and Future Plans
Table 110. Shanghai Dibai Biotechnology Co., Ltd Company Information, Head Office, and Major Competitors
Table 111. Shanghai Dibai Biotechnology Co., Ltd Major Business
Table 112. Shanghai Dibai Biotechnology Co., Ltd Afatinib Dimaleate Product and Solutions
Table 113. Shanghai Dibai Biotechnology Co., Ltd Afatinib Dimaleate Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 114. Shanghai Dibai Biotechnology Co., Ltd Recent Developments and Future Plans
Table 115. Global Afatinib Dimaleate Revenue (USD Million) by Players (2018-2023)
Table 116. Global Afatinib Dimaleate Revenue Share by Players (2018-2023)
Table 117. Breakdown of Afatinib Dimaleate by Company Type (Tier 1, Tier 2, and Tier 3)
Table 118. Market Position of Players in Afatinib Dimaleate, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 119. Head Office of Key Afatinib Dimaleate Players
Table 120. Afatinib Dimaleate Market: Company Product Type Footprint
Table 121. Afatinib Dimaleate Market: Company Product Application Footprint
Table 122. Afatinib Dimaleate New Market Entrants and Barriers to Market Entry
Table 123. Afatinib Dimaleate Mergers, Acquisition, Agreements, and Collaborations
Table 124. Global Afatinib Dimaleate Consumption Value (USD Million) by Type (2018-2023)
Table 125. Global Afatinib Dimaleate Consumption Value Share by Type (2018-2023)
Table 126. Global Afatinib Dimaleate Consumption Value Forecast by Type (2024-2029)
Table 127. Global Afatinib Dimaleate Consumption Value by Application (2018-2023)
Table 128. Global Afatinib Dimaleate Consumption Value Forecast by Application (2024-2029)
Table 129. North America Afatinib Dimaleate Consumption Value by Type (2018-2023) & (USD Million)
Table 130. North America Afatinib Dimaleate Consumption Value by Type (2024-2029) & (USD Million)
Table 131. North America Afatinib Dimaleate Consumption Value by Application (2018-2023) & (USD Million)
Table 132. North America Afatinib Dimaleate Consumption Value by Application (2024-2029) & (USD Million)
Table 133. North America Afatinib Dimaleate Consumption Value by Country (2018-2023) & (USD Million)
Table 134. North America Afatinib Dimaleate Consumption Value by Country (2024-2029) & (USD Million)
Table 135. Europe Afatinib Dimaleate Consumption Value by Type (2018-2023) & (USD Million)
Table 136. Europe Afatinib Dimaleate Consumption Value by Type (2024-2029) & (USD Million)
Table 137. Europe Afatinib Dimaleate Consumption Value by Application (2018-2023) & (USD Million)
Table 138. Europe Afatinib Dimaleate Consumption Value by Application (2024-2029) & (USD Million)
Table 139. Europe Afatinib Dimaleate Consumption Value by Country (2018-2023) & (USD Million)
Table 140. Europe Afatinib Dimaleate Consumption Value by Country (2024-2029) & (USD Million)
Table 141. Asia-Pacific Afatinib Dimaleate Consumption Value by Type (2018-2023) & (USD Million)
Table 142. Asia-Pacific Afatinib Dimaleate Consumption Value by Type (2024-2029) & (USD Million)
Table 143. Asia-Pacific Afatinib Dimaleate Consumption Value by Application (2018-2023) & (USD Million)
Table 144. Asia-Pacific Afatinib Dimaleate Consumption Value by Application (2024-2029) & (USD Million)
Table 145. Asia-Pacific Afatinib Dimaleate Consumption Value by Region (2018-2023) & (USD Million)
Table 146. Asia-Pacific Afatinib Dimaleate Consumption Value by Region (2024-2029) & (USD Million)
Table 147. South America Afatinib Dimaleate Consumption Value by Type (2018-2023) & (USD Million)
Table 148. South America Afatinib Dimaleate Consumption Value by Type (2024-2029) & (USD Million)
Table 149. South America Afatinib Dimaleate Consumption Value by Application (2018-2023) & (USD Million)
Table 150. South America Afatinib Dimaleate Consumption Value by Application (2024-2029) & (USD Million)
Table 151. South America Afatinib Dimaleate Consumption Value by Country (2018-2023) & (USD Million)
Table 152. South America Afatinib Dimaleate Consumption Value by Country (2024-2029) & (USD Million)
Table 153. Middle East & Africa Afatinib Dimaleate Consumption Value by Type (2018-2023) & (USD Million)
Table 154. Middle East & Africa Afatinib Dimaleate Consumption Value by Type (2024-2029) & (USD Million)
Table 155. Middle East & Africa Afatinib Dimaleate Consumption Value by Application (2018-2023) & (USD Million)
Table 156. Middle East & Africa Afatinib Dimaleate Consumption Value by Application (2024-2029) & (USD Million)
Table 157. Middle East & Africa Afatinib Dimaleate Consumption Value by Country (2018-2023) & (USD Million)
Table 158. Middle East & Africa Afatinib Dimaleate Consumption Value by Country (2024-2029) & (USD Million)
Table 159. Afatinib Dimaleate Raw Material
Table 160. Key Suppliers of Afatinib Dimaleate Raw Materials
List of Figures
Figure 1. Afatinib Dimaleate Picture
Figure 2. Global Afatinib Dimaleate Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Afatinib Dimaleate Consumption Value Market Share by Type in 2022
Figure 4. 20 mg
Figure 5. 30 mg
Figure 6. 40 mg
Figure 7. Global Afatinib Dimaleate Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 8. Afatinib Dimaleate Consumption Value Market Share by Application in 2022
Figure 9. Treatment of EGFR Mutated Non-Small Cell Lung Cancer Picture
Figure 10. Treatment of NSCLC Patients with Squamous Cell Carcinoma Histologically Picture
Figure 11. Global Afatinib Dimaleate Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global Afatinib Dimaleate Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global Market Afatinib Dimaleate Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 14. Global Afatinib Dimaleate Consumption Value Market Share by Region (2018-2029)
Figure 15. Global Afatinib Dimaleate Consumption Value Market Share by Region in 2022
Figure 16. North America Afatinib Dimaleate Consumption Value (2018-2029) & (USD Million)
Figure 17. Europe Afatinib Dimaleate Consumption Value (2018-2029) & (USD Million)
Figure 18. Asia-Pacific Afatinib Dimaleate Consumption Value (2018-2029) & (USD Million)
Figure 19. South America Afatinib Dimaleate Consumption Value (2018-2029) & (USD Million)
Figure 20. Middle East and Africa Afatinib Dimaleate Consumption Value (2018-2029) & (USD Million)
Figure 21. Global Afatinib Dimaleate Revenue Share by Players in 2022
Figure 22. Afatinib Dimaleate Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 23. Global Top 3 Players Afatinib Dimaleate Market Share in 2022
Figure 24. Global Top 6 Players Afatinib Dimaleate Market Share in 2022
Figure 25. Global Afatinib Dimaleate Consumption Value Share by Type (2018-2023)
Figure 26. Global Afatinib Dimaleate Market Share Forecast by Type (2024-2029)
Figure 27. Global Afatinib Dimaleate Consumption Value Share by Application (2018-2023)
Figure 28. Global Afatinib Dimaleate Market Share Forecast by Application (2024-2029)
Figure 29. North America Afatinib Dimaleate Consumption Value Market Share by Type (2018-2029)
Figure 30. North America Afatinib Dimaleate Consumption Value Market Share by Application (2018-2029)
Figure 31. North America Afatinib Dimaleate Consumption Value Market Share by Country (2018-2029)
Figure 32. United States Afatinib Dimaleate Consumption Value (2018-2029) & (USD Million)
Figure 33. Canada Afatinib Dimaleate Consumption Value (2018-2029) & (USD Million)
Figure 34. Mexico Afatinib Dimaleate Consumption Value (2018-2029) & (USD Million)
Figure 35. Europe Afatinib Dimaleate Consumption Value Market Share by Type (2018-2029)
Figure 36. Europe Afatinib Dimaleate Consumption Value Market Share by Application (2018-2029)
Figure 37. Europe Afatinib Dimaleate Consumption Value Market Share by Country (2018-2029)
Figure 38. Germany Afatinib Dimaleate Consumption Value (2018-2029) & (USD Million)
Figure 39. France Afatinib Dimaleate Consumption Value (2018-2029) & (USD Million)
Figure 40. United Kingdom Afatinib Dimaleate Consumption Value (2018-2029) & (USD Million)
Figure 41. Russia Afatinib Dimaleate Consumption Value (2018-2029) & (USD Million)
Figure 42. Italy Afatinib Dimaleate Consumption Value (2018-2029) & (USD Million)
Figure 43. Asia-Pacific Afatinib Dimaleate Consumption Value Market Share by Type (2018-2029)
Figure 44. Asia-Pacific Afatinib Dimaleate Consumption Value Market Share by Application (2018-2029)
Figure 45. Asia-Pacific Afatinib Dimaleate Consumption Value Market Share by Region (2018-2029)
Figure 46. China Afatinib Dimaleate Consumption Value (2018-2029) & (USD Million)
Figure 47. Japan Afatinib Dimaleate Consumption Value (2018-2029) & (USD Million)
Figure 48. South Korea Afatinib Dimaleate Consumption Value (2018-2029) & (USD Million)
Figure 49. India Afatinib Dimaleate Consumption Value (2018-2029) & (USD Million)
Figure 50. Southeast Asia Afatinib Dimaleate Consumption Value (2018-2029) & (USD Million)
Figure 51. Australia Afatinib Dimaleate Consumption Value (2018-2029) & (USD Million)
Figure 52. South America Afatinib Dimaleate Consumption Value Market Share by Type (2018-2029)
Figure 53. South America Afatinib Dimaleate Consumption Value Market Share by Application (2018-2029)
Figure 54. South America Afatinib Dimaleate Consumption Value Market Share by Country (2018-2029)
Figure 55. Brazil Afatinib Dimaleate Consumption Value (2018-2029) & (USD Million)
Figure 56. Argentina Afatinib Dimaleate Consumption Value (2018-2029) & (USD Million)
Figure 57. Middle East and Africa Afatinib Dimaleate Consumption Value Market Share by Type (2018-2029)
Figure 58. Middle East and Africa Afatinib Dimaleate Consumption Value Market Share by Application (2018-2029)
Figure 59. Middle East and Africa Afatinib Dimaleate Consumption Value Market Share by Country (2018-2029)
Figure 60. Turkey Afatinib Dimaleate Consumption Value (2018-2029) & (USD Million)
Figure 61. Saudi Arabia Afatinib Dimaleate Consumption Value (2018-2029) & (USD Million)
Figure 62. UAE Afatinib Dimaleate Consumption Value (2018-2029) & (USD Million)
Figure 63. Afatinib Dimaleate Market Drivers
Figure 64. Afatinib Dimaleate Market Restraints
Figure 65. Afatinib Dimaleate Market Trends
Figure 66. Porters Five Forces Analysis
Figure 67. Manufacturing Cost Structure Analysis of Afatinib Dimaleate in 2022
Figure 68. Manufacturing Process Analysis of Afatinib Dimaleate
Figure 69. Afatinib Dimaleate Industrial Chain
Figure 70. Methodology
Figure 71. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Boehringer Ingelheim Pharmaceuticals APExBIO Technology LLC Carbosynth Ltd Biorbyt Cayman Chemical Company Target Molecule Corp. Frontier Specialty Chemicals Combi-Blocks Selleck Chemicals AvaChem Scientific Advanced ChemBlocks Inc Glpbio Nanjing Xize Pharmaceutical Technology Co., Ltd Shandong Haiwo Biotechnology Co., Ltd J&K Scientific Shanghai McLin Biochemical Technology Co., Ltd Beijing Sjar Technology Development Co., Ltd. Beijing Wokai Biotechnology Co., Ltd Ningbo Zhenlei Chemical Co., Ltd. Beijing Mreda Technology Co., Ltd MedBio Pharmaceutical Technology Inc Shanghai Dibai Biotechnology Co., Ltd
Related Reports
16 Jan 2024
Pharma & Healthcare
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
